Psoriatic Arthritis
Feature
Compounding rules challenge practice norms
In a tighter regulatory environment, a routine part of rheumatology practice is called into question.
From the Journals
Secukinumab beat etanercept in 52-week psoriasis quality of life analysis
Secukinumab was associated with faster and greater improvements in self-reported quality of life in psoriasis patients, compared with etanercept...
Conference Coverage
What’s old is new in topical psoriasis therapy
WAILEA, HAWAII – Fixed-combination halobetasol/tazarotene lotion proves safe and effective in phase II study.
Conference Coverage
Ixekizumab found superior to ustekinumab in psoriasis at 24 weeks
ORLANDO – At 24 weeks, the IL-17A blocker ixekizumab was superior to the IL-12/IL-23 blocker ustekinumab in moderate to severe plaque psoriasis....
From the Journals
Shingles vaccine deemed effective in people with autoimmune disease
Older adults with an autoimmune disease benefited for about 5 years before the vaccine’s effectiveness began to wane.
Conference Coverage
Clinicians still seek the best uses for apremilast
WAILEA, HAWAII – An expert calls apremilast outmatched for moderate to severe disease, but off-label use for moderate disease and other...
Conference Coverage
Adalimumab for psoriasis: Blocking TNF-alpha had no effect on vascular inflammation
A study evaluating the effects of blocking TNF-alpha on vascular inflammation in adults with psoriasis raises more questions than answers.
News
CDC: Greater activity limitations accompany rising arthritis prevalence
Physical activity and weight loss may help patients with arthritis retain a higher range of motion.
Conference Coverage
Biosimilars: No big dollar savings, but are clinically ‘dead on’
SNOWMASS, COLO. – Cost savings seen with biosimilars in European countries won’t happen in the United States, but studies are beginning to show...
Conference Coverage
Dactylitis signals more severe psoriatic arthritis
SNOWMASS, COLO. – Studies of dactylitis and enthesitis – two commonly misdiagnosed extra-articular manifestations of psoriatic arthritis – are...
Conference Coverage
CIMPASI-1 and -2 show certolizumab pegol benefits patients with severe plaque psoriasis
ORLANDO – Results from two phase III trials indicated the tumor necrosis factor alpha inhibitor certolizumab pegol led to significant improvements...